- Home
- CDXS
CDXS
Codexis Inc.
as 10-17-2025 4:00pm EST
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 216.6M | IPO Year: | 2010 |
| Target Price: | $11.00 | AVG Volume (30 days): | 542.5K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.90 - $6.08 | Next Earning Date: | 10-30-2025 |
| Revenue: | $57,164,000 | Revenue Growth: | -6.12% |
| Revenue Growth (this year): | 12.88% | Revenue Growth (next year): | 21.64% |
Stock Insider Trading Activity of Codexis Inc. (CDXS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Erbez Georgia | CDXS | Chief Financial Officer | Oct 13 '25 | Sell | $2.51 | 6,239 | $15,628.70 | 70,636 | |
| MOORE ALISON | CDXS | Chief Technical Officer | Oct 13 '25 | Sell | $2.51 | 6,239 | $15,629.32 | 169,332 |
Latest Codexis Inc. News
CDXS Breaking Stock News: Dive into CDXS Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 months ago
With 59% ownership, Codexis, Inc. (NASDAQ:CDXS) boasts of strong institutional backing
GlobeNewswire
5 months ago
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA
GlobeNewswire
5 months ago
Codexis to Participate in Jefferies Global Healthcare Conference
Simply Wall St.
5 months ago
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Thomson Reuters StreetEvents
5 months ago
Q1 2025 Codexis Inc Earnings Call
GuruFocus.com
5 months ago
Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with ...
Zacks
5 months ago
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates
MT Newswires
5 months ago
Codexis Q1 Loss Widens, Revenue Declines; Shares Down
Compare CDXS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CDXS Codexis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.